StocksMediumUpdated×2•Originally published 20 November 2026•Updated 20 November 2026•
4 min read

Biotricity Quarterly Revenue Rises to $4,334,447 as Gross Margin Improves

By

Key Facts

1Quarterly revenue was $4,334,447, compared with $3,885,795 a year earlier.
2Gross profit rose to $3,608,714, and gross margin improved to 83.3%.
3Net loss before preferred dividends widened to $808,161 and included a derivative loss of $151,460.
4Cash was $268,998 and the working capital deficit was $32,293,286 on September 30, 2026.
5The lender’s forbearance expires on December 31, 2026.

Biotricity reported revenue of $4,334,447 for the quarter ended September 30, 2026, compared with $3,885,795 in the year-earlier period, an increase of $448,652, according to its filing with the U.S. Securities and Exchange Commission. Gross profit rose 13.4% to $3,608,714 from $3,181,498, while gross margin increased to 83.3% from 81.9%. Operating income was $338,715, compared with $273,819 a year earlier. These figures show revenue growth and improved operating profitability during the quarter. But net loss before preferred dividends widened to $808,161 from $690,913, as the result was affected by a loss from the change in fair value of derivative liabilities.

Revenue growth relied heavily on technology fees, which accounted for 91.8% of total revenue, compared with 90.4% in the year-earlier period, according to the company’s filing. By contrast, device sales made up 8.2% of revenue, falling about 5.1% year over year to $0.4 million. Total operating expenses were $3,269,999 for the quarter, including $884,501 for research and development. The company said higher research and development expenses were primarily related to increased costs for prototyping and regulatory testing. It described those costs as tied to developing new technologies for its platform and improving its products.

For the six months ended September 30, 2026, revenue was $8,611,403, compared with $7,759,788 in the comparable period, and gross margin rose to 82.9% from 81.2%. The company said it generated $511,000 in cash from operating activities in the first half, compared with $42,000 in the comparable period. But it reported earnings before interest, taxes, depreciation and amortization, a non-GAAP measure, of about $315,000, compared with about $706,000. It attributed the decline mainly to noncash stock-based compensation of about $340,000, compared with about $12,000 a year earlier. The company said collections and accrued liabilities were among the factors affecting cash flows.

Cash and cash equivalents were $268,998 on September 30, 2026, while the working capital deficit reached $32,293,286, compared with $31,284,762 on March 31, 2026. The company said these conditions raise substantial doubt about its ability to continue as a going concern for one year from the date the financial statements are issued. Management’s plans to support liquidity include continuing to grow recurring technology-fee revenue, obtaining additional financing and refinancing the term loan. However, the company said these plans do not alleviate the substantial doubt about its ability to continue as a going concern. The liquidity position adds to the wider net loss, despite improved operating income and operating cash flow in the first half.

Regarding the loan, Runway Growth Finance Corp. agreed to forbear from exercising its rights and remedies through December 31, 2026, according to the filing. Management said it expects to obtain a further extension beyond that date until the term loan is refinanced. The filing said refinancing and additional financing are part of management’s plans to address liquidity needs, without alleviating the substantial doubt about the company’s ability to continue as a going concern. The current forbearance is set to expire about three months after the end of the reported fiscal period. An extension and refinancing therefore remain anticipated developments in the company’s financial trajectory.

On the commercial front, the company said its selection for a charitable heart-screening program was confirmed during October 2026, and it expects the program to include deployment of at least 1,000 devices. It cautioned, however, that there is no guarantee regarding the timing or scale of deployment, or the revenue that will be recognized. The national agreement cited in the filing includes an 18-month pilot in 6 states, with the partner receiving a 30% share. The scale of deployment and potential revenue remain tied to the pilot’s results and the terms of implementation. BTCY shares closed at $0.045 on November 19, 2026, according to EL7 data.

Sources

Open on chart